Can lung cancer patients safely stop immunotherapy early? new trial investigates.
NCT ID NCT03469960
First seen Nov 18, 2025 · Last updated May 09, 2026 · Updated 15 times
Summary
This study looked at 265 people with advanced non-small cell lung cancer whose tumors have a protein called PD-L1. All patients received a combination of two immunotherapy drugs (nivolumab and ipilimumab) for 6 months. Then, half stopped treatment and were watched closely, while the other half continued the drugs until their cancer got worse. The goal was to see if stopping early is just as effective, while reducing side effects and improving quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HP Hopital Tenon - Pneumologie
Paris, 75020, France
-
AP-HP Hôpital Bichat
Paris, France
-
Amiens - CHU
Amiens, France
-
Angers - CHU
Angers, 49000, France
-
Annecy - CH
Annecy, 74374, France
-
Argenteuil -CH
Argenteuil, 95100, France
-
Avignon - CH
Avignon, France
-
Bordeaux - Polyclinique Nord
Bordeaux, France
-
Boulogne - Ambroise Paré
Boulogne-Billancourt, France
-
CH
Cholet, France
-
CH Chambery
Chambéry, France
-
CH Lyon Sud - Pneumologie
Lyon, France
-
CH de Chauny
Chauny, France
-
CH de Pontoise
Cergy-Pontoise, France
-
CH de Villefranche - Pneumologie
Villefranche, France
-
CHRU Grenoble
Grenoble, France
-
CHRU de Lille
Lille, France
-
CHRU de Tours
Tours, France
-
CHU Nîmes
Nîmes, France
-
CHU Toulouse
Toulouse, France
-
CHU de Limoges
Limoges, France
-
Caen - CHU Côte de Nacre
Caen, 14000, France
-
Cahors - CH
Cahors, 46000, France
-
Centre Antoine Lacassagne
Nice, France
-
Centre Hospitalier - Pneumologie
Le Mans, 72000, France
-
Centre René Huguenin
Saint-Cloud, France
-
Clamart - Hôpital Percy
Clamart, 92140, France
-
Clermont Ferrand - CHU
Clermont-Ferrand, 63000, France
-
Colmar - CH
Colmar, 68000, France
-
Dijon - CAC
Dijon, 21000, France
-
GH Paris Saint-Joseph
Paris, France
-
HIA Begin
Saint-Mandé, France
-
Hôpital Saint Louis APHP
Paris, France
-
ICL Lucien Neuwirth
Saint-Priest-en-Jarez, France
-
Institut Paoli Calmette
Marseille, France
-
La Roche Sur Yon - CH
La Roche-sur-Yon, 85925, France
-
Marseille - Hôpital Européen
Marseille, France
-
Mont de Marsan - CH
Mont-de-Marsan, 40000, France
-
Mulhouse - CH
Mulhouse, 68000, France
-
Nantes - Centre René Gauducheau
Nantes, 44805, France
-
Orléans - CH
Orléans, 45000, France
-
Paris - Institut Curie
Paris, France
-
Rouen - CHU
Rouen, 76000, France
-
Saint Quentin - CH
Saint-Quentin, 02100, France
-
Suresnes - Hopital Foch
Suresnes, 92151, France
-
Toulon - CHI
Toulon, 83000, France
-
Versailles - CH
Versailles, 78157, France
Conditions
Explore the condition pages connected to this study.